Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.06
DRAD's Cash-to-Debt is ranked lower than
93% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. DRAD: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
DRAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 150.72 Max: No Debt
Current: 0.06
Equity-to-Asset 0.58
DRAD's Equity-to-Asset is ranked lower than
52% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. DRAD: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
DRAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.99  Med: 0.81 Max: 0.85
Current: 0.58
-1.99
0.85
Debt-to-Equity 0.36
DRAD's Debt-to-Equity is ranked lower than
51% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. DRAD: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
DRAD' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.21  Med: 0.01 Max: 0.48
Current: 0.36
-0.21
0.48
Debt-to-EBITDA 2.74
DRAD's Debt-to-EBITDA is ranked higher than
52% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. DRAD: 2.74 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DRAD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.01  Med: 0.09 Max: 2.74
Current: 2.74
-0.01
2.74
Piotroski F-Score: 4
Altman Z-Score: 0.62
Beneish M-Score: -3.48
WACC vs ROIC
30.35%
-11.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -3.07
DRAD's Operating Margin % is ranked lower than
56% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. DRAD: -3.07 )
Ranked among companies with meaningful Operating Margin % only.
DRAD' s Operating Margin % Range Over the Past 10 Years
Min: -11.73  Med: -1.88 Max: 4.56
Current: -3.07
-11.73
4.56
Net Margin % -9.93
DRAD's Net Margin % is ranked lower than
57% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. DRAD: -9.93 )
Ranked among companies with meaningful Net Margin % only.
DRAD' s Net Margin % Range Over the Past 10 Years
Min: -11.06  Med: -0.67 Max: 35.58
Current: -9.93
-11.06
35.58
ROE % -19.18
DRAD's ROE % is ranked lower than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. DRAD: -19.18 )
Ranked among companies with meaningful ROE % only.
DRAD' s ROE % Range Over the Past 10 Years
Min: -19.18  Med: -0.87 Max: 49.86
Current: -19.18
-19.18
49.86
ROA % -11.72
DRAD's ROA % is ranked lower than
55% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. DRAD: -11.72 )
Ranked among companies with meaningful ROA % only.
DRAD' s ROA % Range Over the Past 10 Years
Min: -11.72  Med: -0.69 Max: 40.82
Current: -11.72
-11.72
40.82
ROC (Joel Greenblatt) % -9.47
DRAD's ROC (Joel Greenblatt) % is ranked lower than
55% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. DRAD: -9.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DRAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -52.2  Med: -9.31 Max: 34.16
Current: -9.47
-52.2
34.16
3-Year Revenue Growth Rate 34.40
DRAD's 3-Year Revenue Growth Rate is ranked higher than
93% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. DRAD: 34.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DRAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -90.7  Med: -3.5 Max: 35.4
Current: 34.4
-90.7
35.4
3-Year EBITDA Growth Rate 79.40
DRAD's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. DRAD: 79.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DRAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -92.6  Med: -41 Max: 79.4
Current: 79.4
-92.6
79.4
3-Year EPS without NRI Growth Rate 314.10
DRAD's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. DRAD: 314.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DRAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -92.9  Med: -20.6 Max: 314.1
Current: 314.1
-92.9
314.1
GuruFocus has detected 2 Warning Signs with Digirad Corp DRAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DRAD's 30-Y Financials

Financials (Next Earnings Date: 2018-02-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

DRAD Guru Trades in Q4 2016

Jim Simons 856,100 sh (-0.83%)
» More
Q1 2017

DRAD Guru Trades in Q1 2017

Jim Simons 855,900 sh (-0.02%)
» More
Q2 2017

DRAD Guru Trades in Q2 2017

John Rogers 499,254 sh (New)
Jim Simons 847,400 sh (-0.99%)
» More
Q3 2017

DRAD Guru Trades in Q3 2017

John Rogers 638,042 sh (+27.80%)
Jim Simons 842,900 sh (-0.53%)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-09-30 Add 27.80%0.01%$3.2 - $4.3 $ 2.40-36%638,042
John Rogers 2017-06-30 New Buy0.02%$3.75 - $5.3 $ 2.40-46%499,254
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:KOOL, XCNQ:BLO, OSTO:CLS B, XPAR:ALCOR, NAS:MGCD, TSE:3022, ROCO:4198, OTCPK:BSGM, OSTO:SEZI, XKRX:115480, TSXV:TLT, ASX:MX1, XPAR:STNT, OSTO:PAX, ASX:LBT, LSE:SUN, XKRX:150840, XKRX:226400, OTCPK:PETV, XPAR:DGM » details
Traded in other countries:FDV.Germany,
Headquarter Location:USA
Digirad Corp develops nuclear technology for mobile cardiovascular imaging for various application. The company commercialized the first nuclear gamma camera and offers its products to doctors' offices and hospitals.

Digirad designs and sells nuclear technology for mobile cardiovascular imaging to doctors' offices and hospitals across the United States. The company commercialized the first nuclear gamma camera and offers its products through both sale and leasing options through its digital imaging solutions subsidiary. The company's gamma cameras range from single- to triple-head configuration, with imaging procedures topping 100,000 in 2007.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 46.17
DRAD's Price-to-Owner-Earnings is ranked higher than
93% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. DRAD: 46.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DRAD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.59  Med: 19.4 Max: 68.27
Current: 46.17
3.59
68.27
PB Ratio 0.96
DRAD's PB Ratio is ranked higher than
87% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. DRAD: 0.96 )
Ranked among companies with meaningful PB Ratio only.
DRAD' s PB Ratio Range Over the Past 10 Years
Min: 0.19  Med: 1.2 Max: 2.66
Current: 0.96
0.19
2.66
PS Ratio 0.42
DRAD's PS Ratio is ranked higher than
90% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. DRAD: 0.42 )
Ranked among companies with meaningful PS Ratio only.
DRAD' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.84 Max: 2.11
Current: 0.42
0.12
2.11
Price-to-Free-Cash-Flow 11.11
DRAD's Price-to-Free-Cash-Flow is ranked higher than
92% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. DRAD: 11.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DRAD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.95  Med: 22.94 Max: 168.89
Current: 11.11
4.95
168.89
Price-to-Operating-Cash-Flow 5.93
DRAD's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. DRAD: 5.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DRAD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.5  Med: 14.65 Max: 401.67
Current: 5.93
3.5
401.67
EV-to-EBIT -18.89
DRAD's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. DRAD: -18.89 )
Ranked among companies with meaningful EV-to-EBIT only.
DRAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -174.9  Med: -1.9 Max: 216.4
Current: -18.89
-174.9
216.4
EV-to-EBITDA 9.69
DRAD's EV-to-EBITDA is ranked higher than
81% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. DRAD: 9.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
DRAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.6  Med: 8.1 Max: 161
Current: 9.69
-126.6
161
EV-to-Revenue 0.57
DRAD's EV-to-Revenue is ranked higher than
92% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. DRAD: 0.57 )
Ranked among companies with meaningful EV-to-Revenue only.
DRAD' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.2  Med: 0.4 Max: 1.8
Current: 0.57
-0.2
1.8
Shiller PE Ratio 627.36
DRAD's Shiller PE Ratio is ranked lower than
73% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. DRAD: 627.36 )
Ranked among companies with meaningful Shiller PE Ratio only.
DRAD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 62.5  Med: 92.5 Max: 650.87
Current: 627.36
62.5
650.87
Current Ratio 1.44
DRAD's Current Ratio is ranked lower than
82% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. DRAD: 1.44 )
Ranked among companies with meaningful Current Ratio only.
DRAD' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 4.42 Max: 5.53
Current: 1.44
1.03
5.53
Quick Ratio 1.07
DRAD's Quick Ratio is ranked lower than
80% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. DRAD: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
DRAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.88  Med: 3.86 Max: 4.82
Current: 1.07
0.88
4.82
Days Inventory 24.28
DRAD's Days Inventory is ranked higher than
93% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. DRAD: 24.28 )
Ranked among companies with meaningful Days Inventory only.
DRAD' s Days Inventory Range Over the Past 10 Years
Min: 21.1  Med: 40.36 Max: 54.41
Current: 24.28
21.1
54.41
Days Sales Outstanding 43.11
DRAD's Days Sales Outstanding is ranked higher than
87% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. DRAD: 43.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.31  Med: 42.27 Max: 48.9
Current: 43.11
39.31
48.9
Days Payable 22.81
DRAD's Days Payable is ranked lower than
86% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. DRAD: 22.81 )
Ranked among companies with meaningful Days Payable only.
DRAD' s Days Payable Range Over the Past 10 Years
Min: 6.32  Med: 13.32 Max: 26.51
Current: 22.81
6.32
26.51

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 8.75
DRAD's Dividend Yield % is ranked higher than
98% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 1.38 vs. DRAD: 8.75 )
Ranked among companies with meaningful Dividend Yield % only.
DRAD' s Dividend Yield % Range Over the Past 10 Years
Min: 1.3  Med: 4.26 Max: 10.25
Current: 8.75
1.3
10.25
3-Year Dividend Growth Rate 58.70
DRAD's 3-Year Dividend Growth Rate is ranked higher than
91% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 10.90 vs. DRAD: 58.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DRAD' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 58.7
Current: 58.7
0
58.7
Forward Dividend Yield % 9.36
DRAD's Forward Dividend Yield % is ranked higher than
98% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. DRAD: 9.36 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.75
DRAD's 5-Year Yield-on-Cost % is ranked higher than
93% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. DRAD: 8.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DRAD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.3  Med: 4.26 Max: 10.25
Current: 8.75
1.3
10.25
3-Year Average Share Buyback Ratio -2.40
DRAD's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. DRAD: -2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1344.4  Med: -0.85 Max: 0.6
Current: -2.4
-1344.4
0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.29
DRAD's Price-to-Tangible-Book is ranked higher than
83% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. DRAD: 1.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DRAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.23  Med: 1.44 Max: 3.01
Current: 1.29
0.23
3.01
Price-to-Intrinsic-Value-Projected-FCF 0.71
DRAD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. DRAD: 0.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DRAD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 2.05 Max: 114
Current: 0.71
0.67
114
Price-to-Median-PS-Value 0.48
DRAD's Price-to-Median-PS-Value is ranked higher than
79% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. DRAD: 0.48 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DRAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.05 Max: 2.34
Current: 0.48
0.02
2.34
Earnings Yield (Greenblatt) % -5.27
DRAD's Earnings Yield (Greenblatt) % is ranked lower than
55% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. DRAD: -5.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DRAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -669.5  Med: -7.8 Max: 475
Current: -5.27
-669.5
475

More Statistics

Revenue (TTM) (Mil) $118.56
EPS (TTM) $ -0.59
Beta1.96
Short Percentage of Float0.48%
52-Week Range $1.90 - 5.68
Shares Outstanding (Mil)20.05

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}